207 related articles for article (PubMed ID: 29242093)
1. Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis.
Visa L; Jiménez-Fonseca P; Martínez EA; Hernández R; Custodio A; Garrido M; Viudez A; Buxo E; Echavarria I; Cano JM; Macias I; Mangas M; de Castro EM; García T; Manceñido FÁ; Montes AF; Azkarate A; Longo F; Serrano AD; López C; Hurtado A; Cerdá P; Serrano R; Gil-Negrete A; Carnicero AM; Pimentel P; Ramchandani A; Carmona-Bayonas A;
J Geriatr Oncol; 2018 May; 9(3):254-264. PubMed ID: 29242093
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.
Kang YK; Ryu MH; Park SH; Kim JG; Kim JW; Cho SH; Park YI; Park SR; Rha SY; Kang MJ; Cho JY; Kang SY; Roh SY; Ryoo BY; Nam BH; Jo YW; Yoon KE; Oh SC
Ann Oncol; 2018 May; 29(5):1220-1226. PubMed ID: 29438463
[TBL] [Abstract][Full Text] [Related]
3. Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Fanotto V; Fornaro L; Bordonaro R; Rosati G; Rimassa L; Di Donato S; Santini D; Tomasello G; Leone F; Silvestris N; Stragliotto S; Scartozzi M; Giampieri R; Nichetti F; Antonuzzo L; Cinieri S; Avallone A; Pellegrino A; Melisi D; Vasile E; Gerratana L; Aprile G
J Geriatr Oncol; 2019 Jul; 10(4):591-597. PubMed ID: 30551958
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry.
Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Sánchez Cánovas M; Hernández R; Pericay C; Echavarria I; Lacalle A; Visa L; Rodríguez Palomo A; Mangas M; Cano JM; Buxo E; Álvarez-Manceñido F; García T; Lorenzo JE; Ferrer-Cardona M; Viudez A; Azkarate A; Ramchandani A; Arias D; Longo F; López C; Sánchez Bayona R; Limón ML; Díaz-Serrano A; Fernández Montes A; Sala P; Cerdá P; Rivera F; Gallego J;
Gastric Cancer; 2018 Jan; 21(1):96-105. PubMed ID: 28393278
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry.
Pérez-Wert P; Custodio A; Jimenez-Fonseca P; Carmona-Bayonas A; Lecumberri A; Cacho Lavin D; Losantos García I; Fernández Montes A; Cano JM; Limón ML; Hernández San Gil R; Diez M; Vidal Tocino R; Macías Declara I; Visa L; Pimentel Cáceres P; Gil Raga M; Martínez Moreno E; Sauri T; Martín Richard M; Granja M; Cerdà P; Gómez González L; Mérida-García A; Ruiz Martín M; Gallego J;
Gastric Cancer; 2024 Jan; 27(1):131-145. PubMed ID: 37964032
[TBL] [Abstract][Full Text] [Related]
6. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
7. Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry.
Jiménez Fonseca P; Carmona-Bayonas A; Hernández R; Custodio A; Cano JM; Lacalle A; Echavarria I; Macias I; Mangas M; Visa L; Buxo E; Álvarez Manceñido F; Viudez A; Pericay C; Azkarate A; Ramchandani A; López C; Martinez de Castro E; Fernández Montes A; Longo F; Sánchez Bayona R; Limón ML; Diaz-Serrano A; Martin Carnicero A; Arias D; Cerdà P; Rivera F; Vieitez JM; Sánchez Cánovas M; Garrido M; Gallego J
Br J Cancer; 2017 Sep; 117(6):775-782. PubMed ID: 28765618
[TBL] [Abstract][Full Text] [Related]
8. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
[TBL] [Abstract][Full Text] [Related]
9. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
10. Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin.
Nishikawa K; Yamada Y; Ishido K; Gotoh M; Bando H; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hamada C; Hyodo I
Gastric Cancer; 2017 Jul; 20(4):640-645. PubMed ID: 27822684
[TBL] [Abstract][Full Text] [Related]
11. Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer.
Sylvie L; Silvia S; Salah-Eddin AB; Markus F; Florian L; Peter TP; Bernhard H; Martin A; Alexander N
Eur J Cancer; 2015 Sep; 51(14):1918-26. PubMed ID: 26216588
[TBL] [Abstract][Full Text] [Related]
12. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
13. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
Kondoh C; Kadowaki S; Komori A; Narita Y; Taniguchi H; Ura T; Ando M; Muro K
Gastric Cancer; 2018 Nov; 21(6):1050-1057. PubMed ID: 29658055
[TBL] [Abstract][Full Text] [Related]
14. On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry.
Carmona-Bayonas A; Jiménez-Fonseca P; Lorenzo ML; Ramchandani A; Martínez EA; Custodio A; Garrido M; Echavarría I; Cano JM; Barreto JE; García TG; Manceñido FÁ; Lacalle A; Cardona MF; Mangas M; Visa L; Buxó E; Azkarate A; Díaz-Serrano A; Montes AF; Rivera F
J Natl Compr Canc Netw; 2016 Nov; 14(11):1379-1388. PubMed ID: 27799509
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
Wang Y; Zhuang RY; Yu YY; Yu S; Hou J; Ji Y; Sun YH; Shen KT; Shen ZB; Liu FL; Zhao NQ; Liu TS
Oncotarget; 2016 Nov; 7(46):76298-76307. PubMed ID: 27602586
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
18. Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry.
Viúdez A; Carmona-Bayonas A; Gallego J; Lacalle A; Hernández R; Cano JM; Macías I; Custodio A; Martínez de Castro E; Sánchez A; Iglesia L; Reguera P; Visa L; Azkarate A; Sánchez-Cánovas M; Mangas M; Limón ML; Martínez-Torrón A; Asensio E; Ramchandani A; Martín-Carnicero A; Hurtado A; Cerdà P; Garrido M; Sánchez-Bayonas R; Serrano R; Jiménez-Fonseca P;
Clin Transl Oncol; 2020 May; 22(5):734-750. PubMed ID: 31385226
[TBL] [Abstract][Full Text] [Related]
19. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
